Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/nanosonics-ltd" target="_blank" data-smartkarma-citation="entities:3831:1" rel="noopener">Nanosonics Ltd (NAN AU)</a> is on track to launch its newly approved endoscope cleaning device, Coris in the U.S. in Q1FY26.</li>
<li>FY25 performance is expected to beat revised guidance. Consensus is expecting revenue growth of 14% for FY25, matching the higher end of the revised guidance.</li>
<li>Nanosonics shares have a high short interest (6.65%) in ASX. We may see some short squeeze as the company entering eventful Q1FY26 (new launch, FY25 result announcement, FY26 guidance).</li>
</ul>



Nanosonics Ltd (NAN AU) is on track to launch its newly approved endoscope cleaning device, Coris in the U.S. in Q1FY26.
FY25 performance is expected to beat revised guidance. Consensus is expecting revenue growth of 14% for FY25, matching the higher end of the revised guidance.
Nanosonics shares have a high short interest (6.65%) in ASX. We may see some short squeeze as the company entering eventful Q1FY26 (new launch, FY25 result announcement, FY26 guidance).


Nanosonics Ltd (NAN AU): Two Upcoming Catalysts to Set Future Direction

Financial News, Analysis and Data, FNArena

FNArena

Financial News, Analysis and Data

Online financial media company focused on Australian equities, with a global perspective

<ul>
<li>Update on changes to and revisions of analysts' Best Ideas and Conviction Calls, as well as Model Portfolio compositions</li>
</ul>


Update on changes to and revisions of analysts' Best Ideas and Conviction Calls, as well as Model Portfolio compositions


Rudi's View: CBA, Life360, ResMed, Zip & More

Index Rebal/Special Situations, Quiddity Advisors

Janaghan Jeyakumar, CFA

Index Rebal/Special Situations

Quiddity Advisors

Pan-Asia Catalysts/Events

Index Rebalance

<ul>
<li>Couple of days ago, I published my index change expectations for the ASX index family in the run up to the September 2025 index review (<a href="https://www.smartkarma.com/insights/quiddity-leaderboard-asx-sep25-spartan-ramelius-deal-consequences-many-high-impact-index-changes" target="_blank" rel="noopener">link</a>).</li>
<li>After market close yesterday, the index provider announced a market consultation on potential changes to the index methodology which could become effective during the September review if it gets approved.</li>
<li>This is a short insight with our revised ranks for the potential ADDs and DELs <em>assuming the market consultation gets approved.</em>
</li>
</ul>


Couple of days ago, I published my index change expectations for the ASX index family in the run up to the September 2025 index review (link).
After market close yesterday, the index provider announced a market consultation on potential changes to the index methodology which could become effective during the September review if it gets approved.
This is a short insight with our revised ranks for the potential ADDs and DELs assuming the market consultation gets approved.



Quiddity Leaderboard ASX Sep25: Update with New Important Market Consultation Implications

Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Quantitative Analysis

<ul>
<li>We analyzed the changes in short interest of ASX Stocks as of Jun 6th (reported yesterday). The aggregated short interest was USD27.4bn.</li>
<li>We tabulate league tables for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.</li>
<li>We highlight short interest changes in IDP Education, Sigma Pharmaceuticals, Evolution Mining, CSL.</li>
</ul>


We analyzed the changes in short interest of ASX Stocks as of Jun 6th (reported yesterday). The aggregated short interest was USD27.4bn.
We tabulate league tables for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.
We highlight short interest changes in IDP Education, Sigma Pharmaceuticals, Evolution Mining, CSL.


ASX Short Interest Weekly (Jun 6th): IDP Education, Sigma Pharmaceuticals, Evolution Mining, CSL

<ul>
<li>We analyzed the changes in short interest of ASX Stocks as of May 16th (reported today). The aggregated short interest was USD26.3bn.</li>
<li>We tabulate league tables for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.</li>
<li>We highlight short interest changes in BHP, Asx, Westpac, Northern Star Resources, Sigma Pharmaceuticals, Santos.</li>
</ul>


We analyzed the changes in short interest of ASX Stocks as of May 16th (reported today). The aggregated short interest was USD26.3bn.
We tabulate league tables for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.
We highlight short interest changes in BHP, Asx, Westpac, Northern Star Resources, Sigma Pharmaceuticals, Santos.


ASX Short Interest Weekly (May 16th): BHP, Asx, Westpac, Northern Star Resources

Australia

Nanosonics Limited is a life science company.  The Company researches, develops, and commercializes a range of disinfection and sterilization technologies that are utilized for infection control and decontamination.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Nanosonics Ltd (NAN AU)